APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Pain Management Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Pain Management Drug Market Outlook and Growth Opportunities 2026

22 December 2025219 pages

Choose your research edition.

Industry ResearchHuman Pain Management Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Pain Management Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Human Pain Management Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Pain Management Drug Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Pain Management Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Human Pain Management Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Pain Management Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Pain Management Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Pain Management Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Pain Management Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Pain Management Drug market include Teva Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Novartis AG, Pfizer Inc., GSK plc., Bayer AG and Bristol Myers Squibb Co., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Pain Management Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Pain Management Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Pain Management Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Pain Management Drug market.

Human Pain Management Drug Segment by Company

Teva Pharmaceuticals Ltd.

Sun Pharmaceutical Industries Ltd.

Sanofi S.A.

Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

Novartis AG

Pfizer Inc.

GSK plc.

Bayer AG

Bristol Myers Squibb Co.

AbbVie Inc. (Allergan plc)

AstraZeneca

Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)

Viatris

Purdue Pharmaceuticals L.P.

Procter & Gamble

Perrigo Company Plc.

Mallinckrodt Pharmaceuticals

F. Hoffmann-La Roche Ltd.

Endo Pharmaceuticals Inc.

Cardinal Health

Boehringer Ingelheim International GmbH

Bausch Health Companies Inc.

Amneal Pharmaceuticals

Abbott Laboratories, Inc.

Human Pain Management Drug Segment by Type

OTC

Rx

Human Pain Management Drug Segment by Application

Hospital

Retail Pharmacy

Other

Human Pain Management Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Pain Management Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Pain Management Drug key companies, revenue, market share, and recent developments.

3. To split the Human Pain Management Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Pain Management Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Pain Management Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Human Pain Management Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Pain Management Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Pain Management Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Pain Management Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Pain Management Drug industry.

Chapter 3: Detailed analysis of Human Pain Management Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Pain Management Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Pain Management Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Pain Management Drug Industry Trends Table 2. Human Pain Management Drug Industry Drivers Table 3. Human Pain Management Drug Industry Opportunities and Challenges Table 4. Human Pain Management Drug Industry Restraints Table 5. Global Human Pain Management Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Pain Management Drug Revenue Share by Company (2021-2026) Table 7. Global Human Pain Management Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Pain Management Drug Key Company Manufacturing Base & Headquarters Table 9. Global Human Pain Management Drug Company, Product Type & Application Table 10. Global Human Pain Management Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Pain Management Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of OTC Table 15. Significant Companies of Rx Table 16. Global Human Pain Management Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Human Pain Management Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Human Pain Management Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Human Pain Management Drug Sales Value Share by Type (2021-2026) Table 20. Global Human Pain Management Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Retail Pharmacy Table 23. Significant Companies of Other Table 24. Global Human Pain Management Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Pain Management Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Human Pain Management Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Human Pain Management Drug Sales Value Share by Application (2021-2026) Table 28. Global Human Pain Management Drug Sales Value Share by Application (2027-2032) Table 29. Global Human Pain Management Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Human Pain Management Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Human Pain Management Drug Sales Value Share by Region (2021-2026) Table 32. Global Human Pain Management Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Human Pain Management Drug Sales Value Share by Region (2027-2032) Table 34. Global Human Pain Management Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Human Pain Management Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Human Pain Management Drug Sales Value Market Share by Country (2021-2026) Table 37. Global Human Pain Management Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Human Pain Management Drug Sales Value Market Share by Country (2027-2032) Table 39. Teva Pharmaceuticals Ltd. Company Information Table 40. Teva Pharmaceuticals Ltd. Business Overview Table 41. Teva Pharmaceuticals Ltd. Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Teva Pharmaceuticals Ltd. Human Pain Management Drug Product Portfolio Table 43. Teva Pharmaceuticals Ltd. Recent Development Table 44. Sun Pharmaceutical Industries Ltd. Company Information Table 45. Sun Pharmaceutical Industries Ltd. Business Overview Table 46. Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Product Portfolio Table 48. Sun Pharmaceutical Industries Ltd. Recent Development Table 49. Sanofi S.A. Company Information Table 50. Sanofi S.A. Business Overview Table 51. Sanofi S.A. Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi S.A. Human Pain Management Drug Product Portfolio Table 53. Sanofi S.A. Recent Development Table 54. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Company Information Table 55. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Business Overview Table 56. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Product Portfolio Table 58. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Recent Development Table 59. Novartis AG Company Information Table 60. Novartis AG Business Overview Table 61. Novartis AG Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Novartis AG Human Pain Management Drug Product Portfolio Table 63. Novartis AG Recent Development Table 64. Pfizer Inc. Company Information Table 65. Pfizer Inc. Business Overview Table 66. Pfizer Inc. Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pfizer Inc. Human Pain Management Drug Product Portfolio Table 68. Pfizer Inc. Recent Development Table 69. GSK plc. Company Information Table 70. GSK plc. Business Overview Table 71. GSK plc. Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GSK plc. Human Pain Management Drug Product Portfolio Table 73. GSK plc. Recent Development Table 74. Bayer AG Company Information Table 75. Bayer AG Business Overview Table 76. Bayer AG Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer AG Human Pain Management Drug Product Portfolio Table 78. Bayer AG Recent Development Table 79. Bristol Myers Squibb Co. Company Information Table 80. Bristol Myers Squibb Co. Business Overview Table 81. Bristol Myers Squibb Co. Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bristol Myers Squibb Co. Human Pain Management Drug Product Portfolio Table 83. Bristol Myers Squibb Co. Recent Development Table 84. AbbVie Inc. (Allergan plc) Company Information Table 85. AbbVie Inc. (Allergan plc) Business Overview Table 86. AbbVie Inc. (Allergan plc) Human Pain Management Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. AbbVie Inc. (Allergan plc) Human Pain Management Drug Product Portfolio Table 88. AbbVie Inc. (Allergan plc) Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. AstraZeneca Human Pain Management Drug Product Portfolio Table 93. AstraZeneca Recent Development Table 94. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Company Information Table 95. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Business Overview Table 96. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Product Portfolio Table 98. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Recent Development Table 99. Viatris Company Information Table 100. Viatris Business Overview Table 101. Viatris Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Viatris Human Pain Management Drug Product Portfolio Table 103. Viatris Recent Development Table 104. Purdue Pharmaceuticals L.P. Company Information Table 105. Purdue Pharmaceuticals L.P. Business Overview Table 106. Purdue Pharmaceuticals L.P. Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Purdue Pharmaceuticals L.P. Human Pain Management Drug Product Portfolio Table 108. Purdue Pharmaceuticals L.P. Recent Development Table 109. Procter & Gamble Company Information Table 110. Procter & Gamble Business Overview Table 111. Procter & Gamble Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Procter & Gamble Human Pain Management Drug Product Portfolio Table 113. Procter & Gamble Recent Development Table 114. Perrigo Company Plc. Company Information Table 115. Perrigo Company Plc. Business Overview Table 116. Perrigo Company Plc. Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Perrigo Company Plc. Human Pain Management Drug Product Portfolio Table 118. Perrigo Company Plc. Recent Development Table 119. Mallinckrodt Pharmaceuticals Company Information Table 120. Mallinckrodt Pharmaceuticals Business Overview Table 121. Mallinckrodt Pharmaceuticals Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Mallinckrodt Pharmaceuticals Human Pain Management Drug Product Portfolio Table 123. Mallinckrodt Pharmaceuticals Recent Development Table 124. F. Hoffmann-La Roche Ltd. Company Information Table 125. F. Hoffmann-La Roche Ltd. Business Overview Table 126. F. Hoffmann-La Roche Ltd. Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. F. Hoffmann-La Roche Ltd. Human Pain Management Drug Product Portfolio Table 128. F. Hoffmann-La Roche Ltd. Recent Development Table 129. Endo Pharmaceuticals Inc. Company Information Table 130. Endo Pharmaceuticals Inc. Business Overview Table 131. Endo Pharmaceuticals Inc. Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Endo Pharmaceuticals Inc. Human Pain Management Drug Product Portfolio Table 133. Endo Pharmaceuticals Inc. Recent Development Table 134. Cardinal Health Company Information Table 135. Cardinal Health Business Overview Table 136. Cardinal Health Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Cardinal Health Human Pain Management Drug Product Portfolio Table 138. Cardinal Health Recent Development Table 139. Boehringer Ingelheim International GmbH Company Information Table 140. Boehringer Ingelheim International GmbH Business Overview Table 141. Boehringer Ingelheim International GmbH Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Boehringer Ingelheim International GmbH Human Pain Management Drug Product Portfolio Table 143. Boehringer Ingelheim International GmbH Recent Development Table 144. Bausch Health Companies Inc. Company Information Table 145. Bausch Health Companies Inc. Business Overview Table 146. Bausch Health Companies Inc. Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Bausch Health Companies Inc. Human Pain Management Drug Product Portfolio Table 148. Bausch Health Companies Inc. Recent Development Table 149. Amneal Pharmaceuticals Company Information Table 150. Amneal Pharmaceuticals Business Overview Table 151. Amneal Pharmaceuticals Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Amneal Pharmaceuticals Human Pain Management Drug Product Portfolio Table 153. Amneal Pharmaceuticals Recent Development Table 154. Abbott Laboratories, Inc. Company Information Table 155. Abbott Laboratories, Inc. Business Overview Table 156. Abbott Laboratories, Inc. Human Pain Management Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. Abbott Laboratories, Inc. Human Pain Management Drug Product Portfolio Table 158. Abbott Laboratories, Inc. Recent Development Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Human Pain Management Drug Product Image Figure 2. Global Human Pain Management Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Pain Management Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Pain Management Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. OTC Image Figure 8. Rx Image Figure 9. Global Human Pain Management Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Human Pain Management Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Human Pain Management Drug Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Retail Pharmacy Image Figure 14. Other Image Figure 15. Global Human Pain Management Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Human Pain Management Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Human Pain Management Drug Sales Value Share by Application (2021-2032) Figure 18. Global Human Pain Management Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Human Pain Management Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Human Pain Management Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America Human Pain Management Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Human Pain Management Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Human Pain Management Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Human Pain Management Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Human Pain Management Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Human Pain Management Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America Human Pain Management Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Human Pain Management Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Human Pain Management Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Human Pain Management Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • OTC
  • Rx
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Teva Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Novartis AG
  • Pfizer Inc.
  • GSK plc.
  • Bayer AG
  • Bristol Myers Squibb Co.
  • AbbVie Inc. (Allergan plc)
  • AstraZeneca
  • Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)
  • Viatris
  • Purdue Pharmaceuticals L.P.
  • Procter & Gamble
  • Perrigo Company Plc.
  • Mallinckrodt Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Endo Pharmaceuticals Inc.
  • Cardinal Health
  • Boehringer Ingelheim International GmbH
  • Bausch Health Companies Inc.
  • Amneal Pharmaceuticals
  • Abbott Laboratories, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Pain Management Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Pain Management Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Pain Management Drug Market Dynamics
  1. 2.1 Human Pain Management Drug Industry Trends
  2. 2.2 Human Pain Management Drug Industry Drivers
  3. 2.3 Human Pain Management Drug Industry Opportunities and Challenges
  4. 2.4 Human Pain Management Drug Industry Restraints
3 Human Pain Management Drug Market by Company
  1. 3.1 Global Human Pain Management Drug Company Revenue Ranking in 2025
  2. 3.2 Global Human Pain Management Drug Revenue by Company (2021-2026)
  3. 3.3 Global Human Pain Management Drug Company Ranking (2024-2026)
  4. 3.4 Global Human Pain Management Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Pain Management Drug Company Product Type and Application
  6. 3.6 Global Human Pain Management Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Pain Management Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Pain Management Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Pain Management Drug Market by Type
  1. 4.1 Human Pain Management Drug Type Introduction
  2. 4.1.1 OTC
  3. 4.1.2 Rx
  4. 4.2 Global Human Pain Management Drug Sales Value by Type
  5. 4.2.1 Global Human Pain Management Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Pain Management Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Human Pain Management Drug Sales Value Share by Type (2021-2032)
5 Human Pain Management Drug Market by Application
  1. 5.1 Human Pain Management Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Human Pain Management Drug Sales Value by Application
  6. 5.2.1 Global Human Pain Management Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Pain Management Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Human Pain Management Drug Sales Value Share by Application (2021-2032)
6 Human Pain Management Drug Regional Value Analysis
  1. 6.1 Global Human Pain Management Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Pain Management Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Pain Management Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Pain Management Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Pain Management Drug Sales Value (2021-2032)
  7. 6.3.2 North America Human Pain Management Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Pain Management Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Human Pain Management Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Pain Management Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Pain Management Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Pain Management Drug Sales Value (2021-2032)
  16. 6.6.2 South America Human Pain Management Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Pain Management Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Pain Management Drug Sales Value Share by Country, 2025 VS 2032
7 Human Pain Management Drug Country-level Value Analysis
  1. 7.1 Global Human Pain Management Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Pain Management Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Pain Management Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Pain Management Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Pain Management Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Pain Management Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Pain Management Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals Ltd.
  2. 8.1.1 Teva Pharmaceuticals Ltd. Company Information
  3. 8.1.2 Teva Pharmaceuticals Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceuticals Ltd. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Ltd. Human Pain Management Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Ltd. Recent Developments
  7. 8.2 Sun Pharmaceutical Industries Ltd.
  8. 8.2.1 Sun Pharmaceutical Industries Ltd. Company Information
  9. 8.2.2 Sun Pharmaceutical Industries Ltd. Business Overview
  10. 8.2.3 Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  13. 8.3 Sanofi S.A.
  14. 8.3.1 Sanofi S.A. Company Information
  15. 8.3.2 Sanofi S.A. Business Overview
  16. 8.3.3 Sanofi S.A. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi S.A. Human Pain Management Drug Product Portfolio
  18. 8.3.5 Sanofi S.A. Recent Developments
  19. 8.4 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  20. 8.4.1 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Company Information
  21. 8.4.2 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Business Overview
  22. 8.4.3 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Product Portfolio
  24. 8.4.5 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Human Pain Management Drug Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
  31. 8.6 Pfizer Inc.
  32. 8.6.1 Pfizer Inc. Company Information
  33. 8.6.2 Pfizer Inc. Business Overview
  34. 8.6.3 Pfizer Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Inc. Human Pain Management Drug Product Portfolio
  36. 8.6.5 Pfizer Inc. Recent Developments
  37. 8.7 GSK plc.
  38. 8.7.1 GSK plc. Company Information
  39. 8.7.2 GSK plc. Business Overview
  40. 8.7.3 GSK plc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GSK plc. Human Pain Management Drug Product Portfolio
  42. 8.7.5 GSK plc. Recent Developments
  43. 8.8 Bayer AG
  44. 8.8.1 Bayer AG Company Information
  45. 8.8.2 Bayer AG Business Overview
  46. 8.8.3 Bayer AG Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer AG Human Pain Management Drug Product Portfolio
  48. 8.8.5 Bayer AG Recent Developments
  49. 8.9 Bristol Myers Squibb Co.
  50. 8.9.1 Bristol Myers Squibb Co. Company Information
  51. 8.9.2 Bristol Myers Squibb Co. Business Overview
  52. 8.9.3 Bristol Myers Squibb Co. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol Myers Squibb Co. Human Pain Management Drug Product Portfolio
  54. 8.9.5 Bristol Myers Squibb Co. Recent Developments
  55. 8.10 AbbVie Inc. (Allergan plc)
  56. 8.10.1 AbbVie Inc. (Allergan plc) Company Information
  57. 8.10.2 AbbVie Inc. (Allergan plc) Business Overview
  58. 8.10.3 AbbVie Inc. (Allergan plc) Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Inc. (Allergan plc) Human Pain Management Drug Product Portfolio
  60. 8.10.5 AbbVie Inc. (Allergan plc) Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Human Pain Management Drug Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)
  68. 8.12.1 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Company Information
  69. 8.12.2 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Business Overview
  70. 8.12.3 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Product Portfolio
  72. 8.12.5 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Recent Developments
  73. 8.13 Viatris
  74. 8.13.1 Viatris Company Information
  75. 8.13.2 Viatris Business Overview
  76. 8.13.3 Viatris Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Viatris Human Pain Management Drug Product Portfolio
  78. 8.13.5 Viatris Recent Developments
  79. 8.14 Purdue Pharmaceuticals L.P.
  80. 8.14.1 Purdue Pharmaceuticals L.P. Company Information
  81. 8.14.2 Purdue Pharmaceuticals L.P. Business Overview
  82. 8.14.3 Purdue Pharmaceuticals L.P. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Purdue Pharmaceuticals L.P. Human Pain Management Drug Product Portfolio
  84. 8.14.5 Purdue Pharmaceuticals L.P. Recent Developments
  85. 8.15 Procter & Gamble
  86. 8.15.1 Procter & Gamble Company Information
  87. 8.15.2 Procter & Gamble Business Overview
  88. 8.15.3 Procter & Gamble Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Procter & Gamble Human Pain Management Drug Product Portfolio
  90. 8.15.5 Procter & Gamble Recent Developments
  91. 8.16 Perrigo Company Plc.
  92. 8.16.1 Perrigo Company Plc. Company Information
  93. 8.16.2 Perrigo Company Plc. Business Overview
  94. 8.16.3 Perrigo Company Plc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Perrigo Company Plc. Human Pain Management Drug Product Portfolio
  96. 8.16.5 Perrigo Company Plc. Recent Developments
  97. 8.17 Mallinckrodt Pharmaceuticals
  98. 8.17.1 Mallinckrodt Pharmaceuticals Company Information
  99. 8.17.2 Mallinckrodt Pharmaceuticals Business Overview
  100. 8.17.3 Mallinckrodt Pharmaceuticals Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Mallinckrodt Pharmaceuticals Human Pain Management Drug Product Portfolio
  102. 8.17.5 Mallinckrodt Pharmaceuticals Recent Developments
  103. 8.18 F. Hoffmann-La Roche Ltd.
  104. 8.18.1 F. Hoffmann-La Roche Ltd. Company Information
  105. 8.18.2 F. Hoffmann-La Roche Ltd. Business Overview
  106. 8.18.3 F. Hoffmann-La Roche Ltd. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 F. Hoffmann-La Roche Ltd. Human Pain Management Drug Product Portfolio
  108. 8.18.5 F. Hoffmann-La Roche Ltd. Recent Developments
  109. 8.19 Endo Pharmaceuticals Inc.
  110. 8.19.1 Endo Pharmaceuticals Inc. Company Information
  111. 8.19.2 Endo Pharmaceuticals Inc. Business Overview
  112. 8.19.3 Endo Pharmaceuticals Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Endo Pharmaceuticals Inc. Human Pain Management Drug Product Portfolio
  114. 8.19.5 Endo Pharmaceuticals Inc. Recent Developments
  115. 8.20 Cardinal Health
  116. 8.20.1 Cardinal Health Company Information
  117. 8.20.2 Cardinal Health Business Overview
  118. 8.20.3 Cardinal Health Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Cardinal Health Human Pain Management Drug Product Portfolio
  120. 8.20.5 Cardinal Health Recent Developments
  121. 8.21 Boehringer Ingelheim International GmbH
  122. 8.21.1 Boehringer Ingelheim International GmbH Company Information
  123. 8.21.2 Boehringer Ingelheim International GmbH Business Overview
  124. 8.21.3 Boehringer Ingelheim International GmbH Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Boehringer Ingelheim International GmbH Human Pain Management Drug Product Portfolio
  126. 8.21.5 Boehringer Ingelheim International GmbH Recent Developments
  127. 8.22 Bausch Health Companies Inc.
  128. 8.22.1 Bausch Health Companies Inc. Company Information
  129. 8.22.2 Bausch Health Companies Inc. Business Overview
  130. 8.22.3 Bausch Health Companies Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Bausch Health Companies Inc. Human Pain Management Drug Product Portfolio
  132. 8.22.5 Bausch Health Companies Inc. Recent Developments
  133. 8.23 Amneal Pharmaceuticals
  134. 8.23.1 Amneal Pharmaceuticals Company Information
  135. 8.23.2 Amneal Pharmaceuticals Business Overview
  136. 8.23.3 Amneal Pharmaceuticals Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Amneal Pharmaceuticals Human Pain Management Drug Product Portfolio
  138. 8.23.5 Amneal Pharmaceuticals Recent Developments
  139. 8.24 Abbott Laboratories, Inc.
  140. 8.24.1 Abbott Laboratories, Inc. Company Information
  141. 8.24.2 Abbott Laboratories, Inc. Business Overview
  142. 8.24.3 Abbott Laboratories, Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Abbott Laboratories, Inc. Human Pain Management Drug Product Portfolio
  144. 8.24.5 Abbott Laboratories, Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst